ArticleThe oncologist2022

Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.

Pashtoon Murtaza KasiPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.